Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Gruenenthal
Gruenenthal
Activities:
Manufacturing
Research & Development
X
LinkedIn
Trending Articles
OINDPs: Nosey about recent developments?
OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
Transforming healthcare with patient centricity
In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Compact process thermostat for efficient temperature control in the laboratory
The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
AviadoBio expands presence at Canary Wharf
The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Research & Development
Catalent and Grünenthal announce manufacturing collaboration
In this phase, Catalent supported Grünenthal with the development of a bioavailability enhanced formulation
Grünenthal appoints Gabriel Baertschi as Chairman and Chief Executive
He follows Prof. Dr Eric-Paul Paques who retires after 23 years with the company
Finance
Grünenthal Group agrees to buy Almirall's operations in Mexico
The deal is a key element of the German Group's strategy to strengthen its footprint in Latin America
Finance
Gruenenthal completes acquisition of Empresas Andromaco
Almost doubles sales in Latin America
Research & Development
Xention and Grünenthal sign research agreement
To focus on new drugs to treat chronic pain
Subscribe now